The Molecular Basis of the Action of Disulfiram as a Modulator of the Multidrug Resistance-Linked ATP Binding Cassette Transporters MDR1 (ABCB1) and MRP1 (ABCC1)

Molecular Pharmacology

Volumn 65, Issue 3, 2004, Pages 675-684

  Sauna, Zuben E ^a   Peng, Xiang Hong ^a   Nandigama, Krishnamachary ^a   Tekle, Samrawit ^a   Ambudkar, Suresh V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; AZIDOPINE; CYCLOSPORIN A; CYSTEINE; DISULFIRAM; GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; N ETHYLMALEIMIDE; PRAZOSIN; REVERSIN; TETRAMETHYLRHODAMINE; UNCLASSIFIED DRUG; VALINOMYCIN; VERAPAMIL; VINBLASTINE;

ALCOHOLISM; ANIMAL CELL; ARTICLE; BINDING SITE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISULFIDE BOND; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; EMBRYO; FLUORESCENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROLYSIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; AZIDES; BINDING SITES; CELLS, CULTURED; DIHYDROPYRIDINES; DISULFIRAM; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHOSPHORUS RADIOISOTOPES; PRAZOSIN;

EID: 1342308328     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.3.675     Document Type: Article

References (34)

1. al-Shawi MK, Urbatsch IL, and Senior AE (1994) Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 269:8986-8992.
2. Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592.
3. Cardarelli CO, Aksentijevich I, Pastan I, and Gottesman MM (1995) Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 55:1086-1091.
4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
5. Chick J (1999) Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 20:427-435.
6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 258: 1650-1654.
7. Dudley ME and Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675.
8. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer C, Scheper RJ, and Zaman GJR (1994) Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor-cells by monoclonal-antibodies. Cancer Res 54:4557-4563.
9. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
10. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
11. Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1998) Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system. Methods Enzymol 292:456-473.
12. Kartner N, Evernden-Porelle D, Bradley G, and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (Lond) 316:820-823.
13. Lee K, Belinsky MG, Bell DW, Testa JR, and Kruh GD (1998) Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein canalicular multispecific organic anion transporter-related transporter. Cancer Res 58:2741-2747.
14. Lee K, Klein-Szanto AJP, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 93:1934-1940.
15. Leonard GD, Polgar O, and Bates SE (2002) ABC transporters and inhibitors: New targets, new agents. Curr Opin Investig Drugs 3:1652-1659.
16. Loo TW and Clarke DM (2000a) Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 92:898-902.
17. Loo TW and Clarke DM (2000b) Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites. J Biol Chem 275:19435-19438.
18. Maki N, Hafkemeyer P, and Dey S (2003) Allosteric modulation of human P-glycoprotein: inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278:18132-18139.
19. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, and Callaghan R (2000) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901-11906.
20. Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, and Roninson IB (1997) P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 94:12908-12913.
21. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, and Pastan I (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37:5010-5019.
22. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
23. Sauna ZE and Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 97:2515-2520.
24. Sauna ZE and Ambudkar SV (2001) Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: the two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 276:11653-11661.
25. Sauna ZE, Smith MM, Muller M, and Ambudkar SV (2001a) Functionally similar vanadate-induced 8-azidoadenosine 5‡-α-P-32 diphosphate-trapped transition state intermediates of human P-glycoprotein are generated in the absence and presence of ATP hydrolysis. J Biol Chem 276:21199-21208.
26. Sauna ZE, Smith MM, Muller M, Kerr KM, and Ambudkar SV (2001b) The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481-491.
27. Schuetz JD, Connelly MC, Sun DX, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
28. Scozzafava A, Casini A, and Supuran CT (2002) Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs. Curr Med Chem 9:1167-1185.
29. Shen ML, Lipsky JJ, and Naylor S (2000) Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 60:947-953.
30. Sonneveld P (2000) Multidrug resistance in haematological malignancies. J Intern Med 247:521-534.
31. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
32. Urbatsch IL, al-Shawi MK, and Senior AE (1994) Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 33:7069-7076.
33. Urbatsch IL, Gimi K, Wilke-Mounts S, Lerner-Marmarosh N, Rousseau ME, Gros P, and Senior AE (2001) Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein. J Biol Chem 276:26980-26987.
34. Yakisich JS, Siden A, Eneroth P, and Cruz M (2001) Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 289:586-590.